相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
P. Fernandes et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine
Magdalena Frank et al.
JOURNAL OF IMMUNOLOGY (2015)
Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice
Silvia H. S. P. Pedroso et al.
MICROBIOLOGY-SGM (2015)
Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics
Ysabella Z. A. Van Sebille et al.
CURRENT ONCOLOGY REPORTS (2015)
New dimension in therapeutic targeting of BCL-2 family proteins
Samaher Besbes et al.
ONCOTARGET (2015)
How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology
Simona Frosali et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Upregulation of TLRs and IL-6 as a Marker in Human Colorectal Cancer
Chien-Chang Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis
Deysi V. T. Wong et al.
PLOS ONE (2015)
Inflammasome Activation Is Reactive Oxygen Species Dependent and Mediates Irinotecan-Induced Mucositis through IL-1β and IL-18 in Mice
Raquel D. N. Arifa et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Sridhar Mani et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?
Ju-Xian Sun et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeted inhibition of IL-18 attenuates irinotecaninduced intestinal mucositis in mice
R. C. P. Lima-Junior et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed
Antonio Avallone et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Community-acquired diarrhea associated with Clostridium difficile in an HIV-positive cancer patient: first case report in Latin America
Cecilia L. Costa et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Guidance on the management of diarrhoea during cancer chemotherapy
Jervoise Andreyev et al.
LANCET ONCOLOGY (2014)
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice
R. Guabiraba et al.
MUCOSAL IMMUNOLOGY (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21WAF1 and p27KIP1
Xia Wang et al.
PHARMACOLOGICAL RESEARCH (2014)
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Umang Swami et al.
CURRENT DRUG TARGETS (2013)
Gut microbiota disturbance during antibiotic therapy: a multi-omic approach
Ana Elena Perez-Cobas et al.
GUT (2013)
Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)
Shujuan Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Caspase Functions in Cell Death and Disease
David R. McIlwain et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
Adam B. Roberts et al.
MOLECULAR PHARMACOLOGY (2013)
Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice
Masashi Yasuda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
Roberto Cesar P. Lima-Junior et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways
Agnieszka Kaczmarek et al.
JOURNAL OF PATHOLOGY (2012)
5-Fluorouracil Induced Intestinal Mucositis via Nuclear Factor-κB Activation by Transcriptomic Analysis and In Vivo Bioluminescence Imaging
Chung-Ta Chang et al.
PLOS ONE (2012)
Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice
Zhen-Qian Wu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen
Akinobu Kurita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Loperamide
Claud Regnard et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2011)
Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies
Mariko Wada et al.
SUPPORTIVE CARE IN CANCER (2010)
Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract
Joanne M. Bowen et al.
TOXICOLOGY (2010)
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations
D. E. Peterson et al.
ANNALS OF ONCOLOGY (2009)
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Richard M. Logan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea
Atakan Sezer et al.
MEDICAL ONCOLOGY (2009)
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Alexander Stein et al.
Therapeutic Advances in Medical Oncology (2009)
Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
Andrea M. Stringer et al.
CANCER BIOLOGY & THERAPY (2008)
Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution
Pedro M. G. Soares et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Caspases - An update
Indrajit Chowdhury et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY (2008)
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Vinay K. Puduvalli et al.
NEURO-ONCOLOGY (2008)
Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice:: effect of pentoxifylline and thalidomide
Maria Luisa P. Melo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor
Hongyu Xue et al.
CLINICAL CANCER RESEARCH (2007)
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer:: a randomised study
P. Osterlund et al.
BRITISH JOURNAL OF CANCER (2007)
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy
Joanne M. Bowen et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Toll-like receptors in inflammation, infection and cancer
Keqiang Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss
Joanne M. Bowen et al.
CANCER BIOLOGY & THERAPY (2007)
Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type I responses
Hermann R. Bohnenkamp et al.
CELLULAR IMMUNOLOGY (2007)
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster
R. F. C. Leitao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Role of p53 in irinotecan-induced intestinal cell death and mucosal damage
Joanne M. Bowen et al.
ANTI-CANCER DRUGS (2007)
Celecoxib and mucosal protection: Translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
Milind M. Javle et al.
CLINICAL CANCER RESEARCH (2007)
DAMPs, PAMPs and alarmins: all we need to know about danger
Marco E. Bianchi
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Updated clinical practice guidelines for the prevention and treatment of mucositis
Dorothy M. Keefe et al.
CANCER (2007)
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-α inhibitor
Xiao-Xia Yang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage
Joanne M. Bowen et al.
SUPPORTIVE CARE IN CANCER (2006)
Intestinal microflora and digestive toxicity of irinotecan in mice
G Brandi et al.
CLINICAL CANCER RESEARCH (2006)
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer
Jeffrey A. Jones et al.
SUPPORTIVE CARE IN CANCER (2006)
Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats
RJ Gibson et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis
G Dranitsaris et al.
SUPPORTIVE CARE IN CANCER (2005)
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea
R Sharma et al.
LANCET ONCOLOGY (2005)
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer
M Karthaus et al.
ONCOLOGY (2005)
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea
A Schmittel et al.
ANNALS OF ONCOLOGY (2004)
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
EB Rubenstein et al.
CANCER (2004)
Review article: oral and intestinal mucositis - causes and possible treatments
M Duncan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer
A Alimonti et al.
ANNALS OF ONCOLOGY (2003)
Lessons learned from the irinotecan metabolic pathway
MK Ma et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role
C Blandizzi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer - A multicenter phase II study
L Vamvakas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
Downregulation of topoisomerase 1 in differentiating human intestinal epithelial cells
H Ulukan et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Toll-like receptors: critical proteins linking innate and acquired immunity
S Akira et al.
NATURE IMMUNOLOGY (2001)
Control of irinotecan-induced diarrhea by octreotide after loperamide failure
V Barbounis et al.
SUPPORTIVE CARE IN CANCER (2001)
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan
C Blandizzi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard
LB Saltz et al.
ONCOLOGIST (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer - An open-label multicenter phase II study
M Ychou et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
分享论文
